You have 9 free searches left this month | for more free features.

City

Beijing (1)

Condition

ALK Fusion Protein Expression (1)

ALK Positive (1)

Adjuvant Therapy (1)

NSCLC Stage IIIB (1)

NSCLC Stage IV (1)

Non-Small Cell Lung Cancer (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Phase

phase 2 (1)

Sponsor

Peking University Cancer Hospital & Institute (1)

Sichuan University (1)

Collaborator

Betta Pharmaceuticals Co., Ltd. (2)

Intervention

ensatinib (2)

chemotherapy (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Other (2)

Study Type

Interventional (1)

Observational (1)

ensatinib

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Ensatinib in alK-positive Patients Undergoing Initial Treatment

Recruiting

ALK Positive
+2 more

Ensatinib

Beijing, Beijing, China

Beijing Cancer Hospital

Nov 16, 2021

ALK Fusion Protein Expression, Adjuvant Therapy, NSCLC Trial (Ensatinib, chemo)

Not yet recruiting

ALK Fusion Protein Expression
+2 more

Ensatinib
chemotherapy

(no location specified)

Jan 10, 2022